Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.03 and traded as high as $2.98. Spero Therapeutics shares last traded at $2.94, with a volume of 1,836,464 shares traded.

Spero Therapeutics Stock Up 1.4%

The stock has a market cap of $164.38 million, a P/E ratio of -2.30 and a beta of 1.31. The stock has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $1.03.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. The firm had revenue of $5.87 million for the quarter, compared to analysts’ expectations of $11.00 million. Sell-side analysts anticipate that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Hedge Funds Weigh In On Spero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SPRO. Three Seasons Wealth LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $31,000. XTX Topco Ltd acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $31,000. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $47,000. Prudential Financial Inc. acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $51,000. Finally, Jane Street Group LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $54,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.